Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$44.94 USD
+0.20 (0.45%)
Updated May 10, 2024 04:00 PM ET
After-Market: $44.55 -0.39 (-0.87%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMY 44.94 +0.20(0.45%)
Will BMY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
A Look at Pharma ETFs Post Q1 Earnings
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Other News for BMY
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
UK earnings, trading statements calendar - next 21 days
Success Rate as High as 90% for AI-Discovered Drugs
Bristol Myers' Opdivo fails in Phase 3 lung cancer study
Bristol Myers announces CheckMate -73L trial did not meet primary endpoint